Syndax Announces Participation in March Investor Conferences
Syndax (Nasdaq: SNDX) announced management will participate in three investor conferences in March 2026, including TD Cowen, Leerink Global Healthcare, and Barclays Global Healthcare.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syndax (Nasdaq: SNDX) announced management will participate in three investor conferences in March 2026, including TD Cowen, Leerink Global Healthcare, and Barclays Global Healthcare. CEO Michael A. Metzger will take part in fireside chats on March 2, 11, and 12, 2026.
A live webcast and limited-time replay will be available in the company’s Investor section at www.syndax.com.
Details
News Market Reaction – SNDX
On Feb 23, the day this news came out, SNDX closed 1.07% above the previous close.
Data tracked by StockTitan Argus for the Feb 23 session.
Key Figures
- TD Cowen fireside time
- 1:50 p.m. ET
- TD Cowen 46th Annual Health Care Conference on March 2, 2026
- TD Cowen date
- March 2, 2026
- TD Cowen 46th Annual Health Care Conference fireside chat
- Leerink date
- March 11, 2026
- Leerink Global Healthcare Conference fireside chat
- Leerink fireside time
- 1:40 p.m. ET
- Leerink Global Healthcare Conference
- Barclays date
- March 12, 2026
- Barclays 28th Annual Global Healthcare Conference fireside chat
- Barclays fireside time
- 11:00 a.m. ET
- Barclays 28th Annual Global Healthcare Conference
Historical Context
-
Announced Q4 and full-year 2025 results date and investor call details.
-
CEO fireside chat at Guggenheim Emerging Outlook: Biotech Summit with webcast.
-
Announced 11,600-share option grants to new employees under inducement plan.
-
Reported strong preliminary Revuforj and Niktimvo revenues and cash position.
-
Launched multi-regional Revuforj managed access program outside the U.S.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
- TD Cowen 46th Annual Health Care Conference in Boston, MA, with a fireside chat on Monday, March 2, 2026, at 1:50 p.m. ET.
- Leerink Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Wednesday, March 11, 2026, at 1:40 p.m. ET.
- Barclays 28th Annual Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Thursday, March 12, 2026, at 11:00 a.m. ET.
A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.